BW Healthcare · 21 Oct, 19:57 · Healthcare briefing

Sanofi’s Qfitlia Receives Marketing Authorisation In India For Haemophilia A And B

Sanofi has secured marketing authorisation in India for Qfitlia, a treatment designed for haemophilia A and B.

What it means for you ↓ Courses for this story

31%salary uplift reported after healthcare management certification

13%projected growth in health services roles this decade

2.1xmore interview callbacks with a verified credential

20days to your first credential

The briefing

The story
in brief.

What happened, who it affects, and why it landed on our intelligence desk — in plain English, sixty seconds or less.

Sanofi has secured marketing authorisation in India for Qfitlia, a treatment designed for haemophilia A and B. This regulatory milestone allows the pharmaceutical company to commercialise the product within one of the world’s largest healthcare markets. The approval signifies successful navigation of local regulatory frameworks and positions Sanofi to address unmet medical needs among Indian patients. For industry observers, this represents a significant expansion of Sanofi’s portfolio in the rare disease sector, highlighting the growing importance of emerging markets in global pharmaceutical strategies and the increasing focus on specialised therapeutic solutions for blood disorders.

Employer demand for Healthcare Management skills — indexed growth since 2019
Indicative index of skill mentions in professional job postings for the field this story moves (2019 = 1)

Your move

What this means
for your career.

Every headline redistributes opportunity. Here is who this one rewards — and how to be on the right side of it.

This approval signals a surge in demand for professionals who understand complex regulatory landscapes in emerging markets. You should focus on mastering compliance frameworks specific to India’s pharmaceutical sector. Specialists in market access and health economics will find heightened relevance, as pricing and reimbursement strategies become critical. Consider upskilling in regulatory affairs to navigate future approvals efficiently. Professionals in supply chain management must also prepare for the logistical complexities of distributing specialised cold-chain products across diverse Indian regions. A smart move is to deepen your knowledge of rare disease therapies and local healthcare infrastructure. By aligning your expertise with these niche yet high-growth areas, you position yourself as an indispensable asset in a rapidly evolving biopharmaceutical environment.

For this story, the fields that convert it into pay are Healthcare Management, Compliance And Governance, Supply Chain and AI in Pharmaceuticals — exactly the programmes matched below. The chart shows the indicative salary uplift certified professionals report in each of those fields; every one of them is a click away, from £79, finishing in as few as 20 days.

Indicative salary uplift in the fields matched to this story
Indicative ranges from published continuing-education salary studies, by field — each field is a recommended course below

Matched to this story

Enrol in these
to benefit.

These programmes position you for exactly this shift — online, self-paced, and finishing with a verifiable certificate you can share the day you pass.